A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy (Q84090042)

From Wikidata

Jump to navigation Jump to search

scientific article published on 13 May 2011

Language	Label	Description	Also known as
English	A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy	scientific article published on 13 May 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567184%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567184%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

colorectal cancer

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567184%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567184%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567184%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567184%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Hyun Cheol Chung

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567184%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567184%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Hei Cheul Jeung

3

object named as

Hei-Cheul Jeung

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567184%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

6

object named as

Jae Kyung Roh

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567184%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

publication date

13 May 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567184%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567184%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

30

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567184%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567184%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

1501-1510

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567184%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

https://scigraph.springernature.com/pub.10.1007/s10637-011-9683-8

0 references

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21567184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Are tumours angiogenesis-dependent?

1 reference

https://pubmed.ncbi.nlm.nih.gov/21567184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21567184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiangiogenesis agents in colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21567184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21567184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical pharmacokinetics of oxaliplatin: a critical review

1 reference

https://pubmed.ncbi.nlm.nih.gov/21567184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/21567184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/21567184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway

1 reference

https://pubmed.ncbi.nlm.nih.gov/21567184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21567184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

VEGF-targeted therapy: mechanisms of anti-tumour activity.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21567184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21567184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21567184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21567184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21567184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21567184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/21567184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21567184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21567184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21567184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q84090042&oldid=2143678346"